Trending storyContinuously updated

Biograil raises €20M for oral drug delivery device

1 reports1 report sources1 hours agoUpdate

Get up to speed on this story

AI Summary

Copenhagen-based Biograil has closed a €20 million funding round, with Verve Ventures and Megatrend Invest backing the company. Biograil is developing BIONDD, an oral device meant to deliver therapeutics that would otherwise require injection. Biograil says the capital will fund work toward a planned Phase 1 trial of BIONDD, including non-clinical GLP studies and setting up a GMP manufacturing process, ahead of a larger financing planned for 2027.

AI-generated from reports · 1 hours agoUpdate

Latest updatesNov 4 18:23

Copenhagen's Biograil raises €20M for oral drug delivery device

Report timeline

Follow the reports to understand different sides of the story.

Nov 4

18:23
EU-StartupsTop Deals
Copenhagen's Biograil raises €20M for oral drug delivery device
Copenhagen-based Biograil has closed a €20 million round backed by Verve Ventures and Megatrend Invest.

Trend for this story

Not enough continuous observation data yet; trend chart is not drawn for now.

Subscribe to the newsletters

Free, by email. No account needed. Pick one or both.

Midu WeeklyMondays · funding trends and top roundsSee a sample issue →SF WeeklyFridays · San Francisco startups, rounds and eventsSee a sample issue →

No spam. Unsubscribe anytime by emailing team@midu.si. Want alerts and full data? Sign up free (separate from the newsletter). Privacy.

Not investment advice. Midu summarizes public reports and SEC filings for information only. · Free API · Pricing